连续低剂量环胺加上普得尼松用于治疗复发性和耐火性多发性骨髓瘤,并伴有严重并发症
Haotian Shi1, Wei Wei1, Rong Peng1
1Department of Hematologic Oncology, Zhabei Central Hospital in Shanghai Jing'an District, Shanghai, China.
持续低剂量循环胺和普雷尼松 (CP) 对复发和耐火性多发性骨髓瘤 (RRMM) 患者具有严重并发症是有效的. 添加其他疗法 (CP + X) 进一步改善了结果,对这一具有挑战性的患者群体显示出希望.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 重复性和耐药性多发性骨髓瘤 (RRMM) 患者出现严重并发症时,会面临重大治疗挑战.
- 连续低剂量循环胺与普得尼松 (CP) 结合是一种潜在的治疗选择.
研究的目的:
- 评估CP的计量化疗方案在RRMM患者中具有严重并发症的疗效和安全性.
- 评估 CP 疗程中添加其他疗法 (CP+X) 的影响.
主要方法:
- 追溯分析130名RRMM患者的严重并发症.
- 患者接受了CP疗法;41名患者接受了额外的治疗 (CP+X).
- 评估的结果包括应答率,不良事件,整体存活率 (OS) 和无进展存活率 (PFS).
主要成果:
- 目标反应率 (ORR) 为58.6%,完全缓解率 (CRR) 为4.7%.
- 平均生存期为38.0个月,平均PFS为22.9个月.
- 与单独使用CP相比,CP+X方案显著改善了CRR,OS和PFS. 心脏功能标志物 (亲BNP/BNP,LVEF) 显示有所改善.
结论:
- 计量 CP 化疗是严重并发症的 RRMM 患者的有效治疗方法.
- 将其他疗法 (CP+X) 添加到CP疗法方案中,可以提高治疗疗效和生存结果.
- 在RRMM患者中,CP疗法对心脏功能产生了积极影响.
更多相关视频
10:31Surgical Angiogenesis in Porcine Tibial Allotransplantation: A New Large Animal Bone Vascularized Composite Allotransplantation Model
Published on: August 13, 2017
09:02Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Treatment Resistant Cancers
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
